AR109108A1 - Derivados de aminopiridina y su uso como inhibidores selectivos de alk-2 - Google Patents
Derivados de aminopiridina y su uso como inhibidores selectivos de alk-2Info
- Publication number
- AR109108A1 AR109108A1 ARP170102033A ARP170102033A AR109108A1 AR 109108 A1 AR109108 A1 AR 109108A1 AR P170102033 A ARP170102033 A AR P170102033A AR P170102033 A ARP170102033 A AR P170102033A AR 109108 A1 AR109108 A1 AR 109108A1
- Authority
- AR
- Argentina
- Prior art keywords
- once
- optionally substituted
- alkyl
- compound
- independently selected
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
La presente solicitud se relaciona con un compuesto en forma libre o en forma de sal farmacéuticamente aceptable, a composiciones farmacéuticas que comprenden dicho compuesto y al uso de dicho compuesto en el tratamiento de la osificación heterotópica y fibrodisplasia osificante progresiva. Reivindicación 1: Un compuesto de la fórmula (1) en forma libre ó en forma de sal farmacéuticamente aceptable, en donde L es un enlace, (CH₂)ₙ, -CH(CH₃)-, -O-(CH₂)ₙ-, -C(O)-, -C(O)-NH-(CH₂)ₙ-; n es 1, 2, 3; R¹ se selecciona de cicloalquilo C₃₋₇ opcionalmente sustituido una vez o más de una vez con un sustituyente seleccionado independientemente entre hidroxilo, halógeno, alquilo C₁₋₃; cicloalquilo C₅₋₁₀ puenteado sustituido opcionalmente una vez o más de una vez con un sustituyente seleccionado independientemente entre hidroxilo, hidroxialquilo C₁₋₃; R² y R³ se seleccionan independientemente de H, halógeno, alquilo C₁₋₃; R⁴ es un anillo heterocíclico no aromático que contiene N, que comprende opcionalmente uno o más heteroátomos adicionales seleccionados de N, O ó S, en donde dicho anillo está opcionalmente sustituido una vez o más de una vez con R⁷; R⁷ se selecciona independientemente de alquilo C₁₋₃, hidroxialquilo C₁₋₃, haloalquilo C₁₋₃, alcoxi C₁₋₃alquilo C₁₋₃, haloalcoxi C₁₋₃alquilo C₁₋₃, alquinilo C₂₋₄, cianoalquilo C₁₋₃, (CH₂)ₘ-R⁸; m es 0, 1, 2 ó 3; R⁸ se selecciona a partir de un anillo heterocíclico no aromático saturado o insaturado de 4, 5 ó 6 miembros que comprende uno o más heteroátomos seleccionados de N, O ó S, dicho anillo opcionalmente sustituido una vez o más de una vez con un sustituyente seleccionado independientemente de oxo, SO₂-alquilo C₁₋₃, haloalquilo C₁₋₃; o un cicloalquilo C₃₋₆ opcionalmente sustituido una vez o más de una vez con halo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662364620P | 2016-07-20 | 2016-07-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR109108A1 true AR109108A1 (es) | 2018-10-31 |
Family
ID=60991950
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP170102033A AR109108A1 (es) | 2016-07-20 | 2017-07-20 | Derivados de aminopiridina y su uso como inhibidores selectivos de alk-2 |
Country Status (25)
Country | Link |
---|---|
US (3) | US10710980B2 (es) |
EP (2) | EP3487851B1 (es) |
JP (3) | JP7030776B2 (es) |
KR (5) | KR102559539B1 (es) |
CN (2) | CN114014844A (es) |
AR (1) | AR109108A1 (es) |
AU (4) | AU2017298187B2 (es) |
BR (1) | BR112019000941A2 (es) |
CA (1) | CA3030332A1 (es) |
CY (1) | CY1124967T1 (es) |
DK (1) | DK3487851T3 (es) |
EA (2) | EA037520B1 (es) |
ES (1) | ES2902521T3 (es) |
HR (1) | HRP20211868T1 (es) |
HU (1) | HUE057328T2 (es) |
LT (1) | LT3487851T (es) |
MX (2) | MX2019000837A (es) |
PL (1) | PL3487851T3 (es) |
PT (1) | PT3487851T (es) |
RS (1) | RS62819B1 (es) |
RU (1) | RU2747318C2 (es) |
SI (1) | SI3487851T1 (es) |
TW (4) | TW202336011A (es) |
UY (1) | UY37331A (es) |
WO (1) | WO2018014829A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2017298187B2 (en) | 2016-07-20 | 2019-11-14 | Novartis Ag | Aminopyridine derivatives and their use as selective ALK-2 inhibitors |
BR112022009710A2 (pt) * | 2019-11-22 | 2022-08-09 | Incyte Corp | Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2 |
CN111170893B (zh) * | 2020-01-19 | 2022-04-26 | 郑州依米花手性药物研究有限公司 | Lefamulin的中间体化合物及其在Lefamulin制备中的应用 |
KR20230025444A (ko) * | 2020-06-16 | 2023-02-21 | 인사이트 코포레이션 | 빈혈 치료를 위한 alk2 저해제 |
WO2023198114A1 (zh) * | 2022-04-13 | 2023-10-19 | 杭州邦顺制药有限公司 | Alk2激酶抑制剂 |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5077290A (en) | 1990-10-11 | 1991-12-31 | Merck & Co., Inc. | Morpholine derivatives compositions and use |
EP0677104B1 (en) | 1992-11-17 | 2003-03-19 | Ludwig Institute For Cancer Research | Activin receptor-like kinases, proteins having serine threonine kinase domains and their use |
TW530054B (en) | 1997-09-24 | 2003-05-01 | Duphar Int Res | New piperazine and piperidine compounds |
SE0102439D0 (sv) | 2001-07-05 | 2001-07-05 | Astrazeneca Ab | New compounds |
US6914058B2 (en) * | 2002-01-18 | 2005-07-05 | Dr. Reddy's Laboratories, Limited | Antibacterial compounds: process for their preparation and pharmaceutical compositions containing them |
AU2003234464B2 (en) | 2002-05-03 | 2009-06-04 | Exelixis, Inc. | Protein kinase modulators and methods of use |
AU2003249369A1 (en) | 2002-06-21 | 2004-01-06 | Cellular Genomics, Inc. | Certain amino-substituted monocycles as kinase modulators |
US20040067985A1 (en) | 2002-10-04 | 2004-04-08 | Fortuna Haviv | Method of inhibiting angiogenesis |
SE0203753D0 (sv) | 2002-12-17 | 2002-12-17 | Astrazeneca Ab | New compounds |
FR2850652B1 (fr) * | 2003-01-31 | 2008-05-30 | Aventis Pharma Sa | Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
JP2007521252A (ja) | 2003-04-11 | 2007-08-02 | エスジーエックス ファーマシューティカルズ,インコーポレイティド | 化合物ライブラリーおよび薬剤発見方法 |
EP1758862A1 (en) | 2004-05-27 | 2007-03-07 | Pfizer Limited | Aminopyridine derivatives as selective dopamine d3 agonists |
SA05260265A (ar) | 2004-08-30 | 2005-12-03 | استرازينيكا ايه بي | مركبات جديدة |
WO2006109876A1 (ja) | 2005-04-08 | 2006-10-19 | Eisai R & D Management Co., Ltd. | 不随意運動治療剤 |
WO2007011760A2 (en) | 2005-07-15 | 2007-01-25 | Kalypsys, Inc. | Inhibitors of mitotic kinesin |
GB0517175D0 (en) | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Compounds |
AR059037A1 (es) | 2006-01-17 | 2008-03-12 | Schering Corp | Compuestos para el tratamiento de trastornos inflamatorios |
WO2007123896A2 (en) | 2006-04-18 | 2007-11-01 | The Trustees Of The University Of Pennsylvania | Mutated acvr1 for diagnosis and treatment of fibrodyplasia ossificans progressiva (fop) |
EP2069313A2 (en) | 2006-06-29 | 2009-06-17 | Alantos Pharmaceuticals Holdings, Inc. | Metalloprotease inhibitors |
EA200970250A1 (ru) | 2006-09-05 | 2010-02-26 | Медарекс, Инк. | Антитела к костным морфогенетическим белкам и их рецепторам и способы их применения |
EP2270229A1 (en) | 2006-09-12 | 2011-01-05 | The General Hospital Corporation | Inhibitors of bone morphogenetic protein (BMP) signalling for therapeutical purposes |
UA97813C2 (uk) * | 2006-12-05 | 2012-03-26 | Янссен Фармацевтика Н.В. | Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу |
US8507501B2 (en) | 2008-03-13 | 2013-08-13 | The Brigham And Women's Hospital, Inc. | Inhibitors of the BMP signaling pathway |
EP2303859A4 (en) | 2008-06-20 | 2012-08-22 | Metabolex Inc | ARYL GPR119 AGONISTS AND USES THEREOF |
AU2011292810B2 (en) | 2010-08-20 | 2015-04-30 | Wyeth Llc | Designer osteogenic proteins |
AU2011340167A1 (en) | 2010-12-06 | 2013-07-18 | Piramal Enterprises Limited | Substituted imidazoquinoline derivatives |
WO2012087938A1 (en) | 2010-12-20 | 2012-06-28 | Glaxosmithkline Llc | Quinazolinone derivatives as antiviral agents |
WO2012088438A1 (en) | 2010-12-22 | 2012-06-28 | Eutropics Pharmaceuticals, Inc. | Compositions and methods useful for treating diseases |
ES2699256T3 (es) | 2011-05-23 | 2019-02-08 | Merck Patent Gmbh | Piridina y derivados de pirazina |
KR20190015765A (ko) | 2011-09-09 | 2019-02-14 | 랜티우스 메디컬 이메징, 인크. | 영상화제의 합성 및 사용을 위한 조성물, 방법 및 시스템 |
WO2014051698A1 (en) * | 2012-09-28 | 2014-04-03 | Vanderbilt University | Fused heterocyclic compounds as selective bmp inhibitors |
EP2964651A4 (en) * | 2013-03-04 | 2016-11-30 | Brigham & Womens Hospital | BMP HEMMER AND METHOD OF USE THEREOF |
TR201911151T4 (tr) * | 2013-03-14 | 2019-08-21 | Tolero Pharmaceuticals Inc | Jak2 ve alk2 inhibitörleri ve bunların kullanım yöntemleri. |
EP2970311A4 (en) | 2013-03-14 | 2016-11-23 | Brigham & Womens Hospital | BMP INHIBITORS AND METHODS OF USE |
DK3060550T3 (da) | 2013-10-21 | 2019-07-22 | Merck Patent Gmbh | Heteroarylforbindelser som btk-inhibitorer og anvendelser deraf |
WO2015152183A1 (ja) | 2014-03-31 | 2015-10-08 | 大日本住友製薬株式会社 | 進行性骨化性線維異形成症の予防剤及び治療剤 |
JP6771469B2 (ja) | 2015-01-20 | 2020-10-21 | ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド | 駆虫性化合物、組成物及びこれらの使用方法 |
AU2017298187B2 (en) | 2016-07-20 | 2019-11-14 | Novartis Ag | Aminopyridine derivatives and their use as selective ALK-2 inhibitors |
WO2018106820A1 (en) | 2016-12-07 | 2018-06-14 | Kura Oncology, Inc. | Methods of promoting beta cell proliferation |
-
2017
- 2017-07-18 AU AU2017298187A patent/AU2017298187B2/en active Active
- 2017-07-18 WO PCT/CN2017/093385 patent/WO2018014829A1/en unknown
- 2017-07-18 TW TW112118991A patent/TW202336011A/zh unknown
- 2017-07-18 PL PL17830463T patent/PL3487851T3/pl unknown
- 2017-07-18 TW TW111103316A patent/TWI806385B/zh active
- 2017-07-18 CN CN202111145806.6A patent/CN114014844A/zh active Pending
- 2017-07-18 CA CA3030332A patent/CA3030332A1/en active Pending
- 2017-07-18 ES ES17830463T patent/ES2902521T3/es active Active
- 2017-07-18 EA EA201990343A patent/EA037520B1/ru unknown
- 2017-07-18 LT LTEPPCT/CN2017/093385T patent/LT3487851T/lt unknown
- 2017-07-18 RU RU2019104609A patent/RU2747318C2/ru active
- 2017-07-18 CN CN201780044640.4A patent/CN109641871B/zh active Active
- 2017-07-18 TW TW110101592A patent/TWI755255B/zh active
- 2017-07-18 HU HUE17830463A patent/HUE057328T2/hu unknown
- 2017-07-18 KR KR1020227034980A patent/KR102559539B1/ko active IP Right Grant
- 2017-07-18 DK DK17830463.0T patent/DK3487851T3/da active
- 2017-07-18 KR KR1020237024969A patent/KR20230117248A/ko active IP Right Grant
- 2017-07-18 HR HRP20211868TT patent/HRP20211868T1/hr unknown
- 2017-07-18 MX MX2019000837A patent/MX2019000837A/es unknown
- 2017-07-18 US US16/318,250 patent/US10710980B2/en active Active
- 2017-07-18 BR BR112019000941-8A patent/BR112019000941A2/pt active Search and Examination
- 2017-07-18 EP EP17830463.0A patent/EP3487851B1/en active Active
- 2017-07-18 RS RS20211582A patent/RS62819B1/sr unknown
- 2017-07-18 JP JP2019502675A patent/JP7030776B2/ja active Active
- 2017-07-18 KR KR1020217022916A patent/KR102359707B1/ko active IP Right Grant
- 2017-07-18 EA EA202190285A patent/EA202190285A1/ru unknown
- 2017-07-18 SI SI201731040T patent/SI3487851T1/sl unknown
- 2017-07-18 KR KR1020227003660A patent/KR102454129B1/ko active IP Right Grant
- 2017-07-18 KR KR1020197004529A patent/KR102281550B1/ko active IP Right Grant
- 2017-07-18 EP EP21202619.9A patent/EP3971177A1/en active Pending
- 2017-07-18 TW TW106123900A patent/TWI712598B/zh active
- 2017-07-18 PT PT178304630T patent/PT3487851T/pt unknown
- 2017-07-19 UY UY0001037331A patent/UY37331A/es not_active Application Discontinuation
- 2017-07-20 AR ARP170102033A patent/AR109108A1/es unknown
-
2019
- 2019-01-18 MX MX2021014852A patent/MX2021014852A/es unknown
- 2019-10-10 AU AU2019246857A patent/AU2019246857B2/en active Active
-
2020
- 2020-05-27 US US16/884,666 patent/US10947218B2/en active Active
-
2021
- 2021-02-08 US US17/170,690 patent/US20210155606A1/en active Pending
- 2021-03-04 AU AU2021201424A patent/AU2021201424C1/en active Active
- 2021-12-29 CY CY20211101137T patent/CY1124967T1/el unknown
-
2022
- 2022-02-22 JP JP2022025894A patent/JP7253086B2/ja active Active
-
2023
- 2023-01-19 AU AU2023200265A patent/AU2023200265A1/en active Pending
- 2023-03-24 JP JP2023048083A patent/JP2023089012A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR109108A1 (es) | Derivados de aminopiridina y su uso como inhibidores selectivos de alk-2 | |
AR089671A1 (es) | 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
AR090220A1 (es) | Inhibidores de serina/treonina cinasa | |
AR108709A1 (es) | Compuestos moduladores de fxr (nr1h4) | |
AR092269A1 (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
AR098666A1 (es) | Compuestos de biarilacetamida y sus métodos de uso | |
AR106053A1 (es) | Compuestos imidazo[4,5-c]quinolin-2-ona y su uso para el tratamiento del cáncer | |
AR111314A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
AR089143A1 (es) | Triazolopiridinas sustituidas con actividad inhibidora de ttk | |
AR091156A1 (es) | Nucleosidos de espirooxetano de uracilo | |
AR088828A1 (es) | DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
AR119018A1 (es) | Inhibidores de proteína quinasas dependientes de adn | |
BR112016019462B8 (pt) | Compostos heterocïclicos tricïclicos como inibidores de fosfoinosotida 3-cinase | |
AR094812A1 (es) | Derivado de piridina monocíclico como inhibidor del fgfr | |
AR092809A1 (es) | 3,5-diaminopirazol como inhibidor de quinasa | |
AR094553A1 (es) | Formas de oxadiazolpirazina | |
AR100714A1 (es) | Derivados de alquilo y arilo de compuestos de 1-oxa-4,9-diazaespiro undecano que tienen actividad multimodal contra el dolor | |
AR107321A1 (es) | Compuestos antiproliferativos, y sus composiciones farmacéuticas y usos | |
AR111494A1 (es) | Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer | |
AR090557A1 (es) | DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2 | |
AR109711A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
AR110440A1 (es) | Compuestos para el tratamiento de la enfermedad respiratoria bovina o porcina | |
AR100440A1 (es) | Derivados de carboxamida como inhibidores selectivos de smurf1 | |
AR102972A1 (es) | Compuestos de dihidropirimidin-2-ona y su uso médico | |
AR098844A1 (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias |